Skip to main content

Table 3 Kinase inhibitor classifications

From: Recent advances in pharmacological diversification of Src family kinase inhibitors

Type of kinase inhibitor

Approved drugs

Target site

Type I kinase inhibitors

Bosutinib, Crizotinib, Dasatinib, Erlotinib, Gefitinib, Lapatinib, Pazopanib, Ruxolitinib, Sunitinib, Vandetanib, and Vemurafenib

Active ATP binding sites

Type II kinase inhibitors

Imatinib, Ponatinib

Inactive conformation of Substrate

Type III or allosteric inhibitors

RO0281675

Allosteric sites

Type IV or substrate-directed inhibitors

ON012380

ATP noncompetitive inhibitors

Type V or covalent inhibitors

Ibrutinib, Afatinib, and Neratinib

Cysteine side chains of kinases